R. Adams and K. Alitalo, Molecular regulation of angiogenesis and lymphangiogenesis, Nature Reviews Molecular Cell Biology, vol.17, issue.6, pp.464-78, 2007.
DOI : 10.1016/S0002-9440(10)63851-5

G. Ahn and J. Brown, Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells, Cancer Cell, vol.13, issue.3, 2008.
DOI : 10.1016/j.ccr.2007.11.032

K. Alitalo, T. Tammela, and T. Petrova, Lymphangiogenesis in development and human disease, Nature, vol.36, issue.7070, pp.946-53, 2005.
DOI : 10.1038/ng1383

S. Alkindi, D. Dennison, and A. Pathare, Arterial and Venous Thrombotic Complications with Thalidomide in Multiple Myeloma, Archives of Medical Research, vol.39, issue.2, pp.257-265, 2008.
DOI : 10.1016/j.arcmed.2007.08.005

P. Auguste, S. Lemiere, F. Larrieu-lahargue, and A. Bikfalvi, Molecular mechanisms of tumor vascularization, Critical Reviews in Oncology/Hematology, vol.54, issue.1, pp.53-61, 2005.
DOI : 10.1016/j.critrevonc.2004.11.006

J. Bartlett, K. Dredge, and A. Dalgleish, The evolution of thalidomide and its IMiD derivatives as anticancer agents, Nature Reviews Cancer, vol.18, issue.4, pp.314-336, 2004.
DOI : 10.1016/S0167-5699(97)01118-3

A. Berrier and K. Yamada, Cell???matrix adhesion, Journal of Cellular Physiology, vol.114, issue.3, pp.565-73, 2007.
DOI : 10.1016/j.bbamcr.2004.04.007

A. Bifkalvi, Le rôle du facteur plaquettaire 4 dans la régulation et l'inhibition de l'angiogenèse. Hématologie. 2004 sept-oct, pp.365-374

N. Brindle, P. Saharinen, and K. Alitalo, Signaling and Functions of Angiopoietin-1 in Vascular Protection, Circulation Research, vol.98, issue.8, pp.1014-1037, 2006.
DOI : 10.1161/01.RES.0000218275.54089.12

V. Brower, Tumor angiogenesis???new drugs on the block, Nature Biotechnology, vol.394, issue.10, pp.963-971, 1999.
DOI : 10.1038/28412

R. Cao, A. Eriksson, H. Kubo, K. Alitalo, Y. Cao et al., Comparative Evaluation of FGF-2-, VEGF-A-, and VEGF-C-Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and Permeability, Circulation Research, vol.94, issue.5, pp.664-70, 2004.
DOI : 10.1161/01.RES.0000118600.91698.BB

P. Carmeliet, Angiogenesis in health and disease, Nature Medicine, vol.5, issue.suppl. 1, pp.653-60, 2003.
DOI : 10.1006/mthe.2002.0590

C. Chantrain and Y. Declerck, Les m??talloprot??ases matricielles et leurs inhibiteurs synth??tiques dans la progression tumorale, m??decine/sciences, vol.18, issue.5, pp.565-75, 2002.
DOI : 10.1051/medsci/2002185565

URL : http://www.medecinesciences.org/articles/medsci/pdf/2002/05/medsci2002185p565.pdf

J. Christopher, &. Schofield, J. Peter, and . Ratcliffe, Oxygen sensing by HIF hydroxylases, Nature Reviews Molecular Cell Biology, vol.5, pp.343-354, 2004.

O. Cleaver and D. Melton, Endothelial signaling during development, Nature Medicine, vol.2, issue.6, pp.661-669, 2003.
DOI : 10.1517/14712598.2.8.805

E. Clottes, Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy, Bull Cancer. Feb, vol.92, issue.2, pp.119-146, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00077264

T. Couffinhal, P. Dufourcq, D. Daret, and C. Duplaà, Les mécanismes de l'angiogenèse. Applications médicales et thérapeutiques. Rev Méd Interne, pp.1064-82, 2001.

V. Daubie, R. Pochet, S. Houard, and P. Philippart, Tissue factor: a mini-review, Journal of Tissue Engineering and Regenerative Medicine, vol.267, issue.3, pp.161-170, 2007.
DOI : 10.1042/bj3100605

D. Boüard, S. Guillamo, and J. , Angiogenesis and anti-angiogenic strategies for glioblastoma. Bull Cancer, pp.360-72, 2005.

Y. Delmas, J. Viallard, J. Villeneuve, C. Grosset, J. Pasquet et al., Une nouvelle interface dans l'hémostase et la réaction inflammatoire, pp.825-856, 1921.

C. Desauw and J. Bonneterre, Antineoplastic treatment and venous thrombosis. Bull Cancer, Feb, vol.193, issue.2, pp.171-179, 2006.

L. Drouet, Risque thromboembolique des th??rapeutiques antiangiog??niques utilis??es dans les cancers, Pathologie Biologie, vol.56, issue.4, pp.195-204, 2008.
DOI : 10.1016/j.patbio.2008.02.013

R. Du, K. Lu, C. Petritsch, P. Liu, R. Ganss et al., HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.Cancer Cell, pp.206-226, 2008.

D. Edwards and M. G. Cancer, Proteases ??? invasion and more, Nature, vol.394, issue.6693, pp.527-535, 1998.
DOI : 10.1083/jcb.139.7.1861

M. Eichhorn, A. Kleespies, M. Angele, K. Jauch, and C. Bruns, Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg, pp.371-380, 2007.

L. Eklund and B. Olsen, Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling, Experimental Cell Research, vol.312, issue.5, pp.630-671, 2006.
DOI : 10.1016/j.yexcr.2005.09.002

J. Fayette, J. Soria, and J. Armand, Le ciblage de l???angiogen??se en oncologie, Pathologie Biologie, vol.54, issue.4, pp.199-205, 2006.
DOI : 10.1016/j.patbio.2004.11.003

N. Ferrara and R. Kerbel, Angiogenesis as a therapeutic target, Nature, vol.65, issue.7070, pp.967-74, 2005.
DOI : 10.1158/0008-5472.CAN-05-0626

G. Fong, Mechanisms of adaptive angiogenesis to tissue hypoxia, Angiogenesis, vol.336, issue.1, pp.121-161, 2008.
DOI : 10.4161/cc.6.5.3922

C. Fribourg and C. Denis, Plaquettes et tumeurs, Hématologie, vol.12, issue.6, pp.400-411, 2006.

S. Fukuhara, K. Sako, T. Minami, K. Noda, H. Kim et al., Differential function of Tie2 at cell???cell contacts and cell???substratum contacts regulated by angiopoietin-1, Nature Cell Biology, vol.9, issue.5, pp.513-539, 2008.
DOI : 10.1091/mbc.E05-07-0647

D. Fukumura and R. Jain, Tumor microvasculature and microenvironment: targets for antiangiogenesis and normalization. Microvasc Res, pp.72-84, 2007.

E. Gabison, T. Hoang-xuan, A. Mauviel, and S. Menashi, M??talloprot??inases et angiogen??se, Pathologie Biologie, vol.51, issue.3, pp.161-167, 2003.
DOI : 10.1016/S0369-8114(03)00018-X

M. Galli, F. Elice, C. Crippa, B. Comotti, F. Rodeghiero et al., Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma, Haematologica, vol.89, issue.9, pp.1141-1143, 2004.

G. Gasparini, R. Longo, M. Fanelli, and B. Teicher, Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions, Journal of Clinical Oncology, vol.23, issue.6, pp.1295-311, 2005.
DOI : 10.1200/JCO.2005.10.022

H. Gerhardt, M. Golding, M. Fruttiger, C. Ruhrberg, A. Lundkvist et al., VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia, The Journal of Cell Biology, vol.15, issue.6, pp.1163-77, 2003.
DOI : 10.1002/(SICI)1521-1878(200003)22:3<219::AID-BIES3>3.0.CO;2-A

URL : http://jcb.rupress.org/content/jcb/161/6/1163.full.pdf

F. Gieseler, Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost, Review. Erratum Thromb Haemost, vol.99100, issue.61, pp.1001-7171, 2008.

D. Helley and A. Fischer, Le système de l'hémostase dans la modulation de l'angiogenèse. Hématologie, pp.184-91, 2001.

H. Heloterä and K. Alitalo, The VEGF family, the inside story. Cell, pp.591-593, 2007.

R. Hoch and P. Soriano, Roles of PDGF in animal development. Development, 2003.

B. Hu, P. Guo, Q. Fang, H. Tao, D. Wang et al., Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2, Proceedings of the National Academy of Sciences, vol.62, issue.21, pp.8904-8913, 2003.
DOI : 10.1023/A:1012201300188

N. Hubbard, D. Lim, M. Mukutmoni, A. Cai, and K. Erickson, Expression and regulation of murine macrophage angiopoietin-2, Cellular Immunology, vol.234, issue.2, pp.102-111, 2005.
DOI : 10.1016/j.cellimm.2005.06.001

R. Hynes, A reevaluation of integrins as regulators of angiogenesis, Nature Medicine, vol.4, issue.9, pp.918-939, 2002.
DOI : 10.1038/nm0302-193

E. Iivanainen, L. Nelimarkka, V. Elenius, S. Heikkinen, T. Junttila et al., Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor, The FASEB Journal, vol.17, issue.12, pp.1609-1630, 2003.
DOI : 10.1016/S0092-8674(00)81812-7

H. Izzedine, Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity]. Bull Cancer, pp.981-987, 2007.
DOI : 10.1053/j.ajkd.2007.04.025

R. Jain, Molecular regulation of vessel maturation, Nature Medicine, vol.4, issue.6, pp.685-93, 2003.
DOI : 10.3109/10739689709146803

R. Kalluri, Angiogenesis: Basement membranes: structure, assembly and role in tumour angiogenesis, Nature Reviews Cancer, vol.3, issue.6, pp.422-455, 2003.
DOI : 10.1038/nrc1094

T. Kamba and D. Mcdonald, Mechanisms of adverse effects of anti-VEGF therapy for cancer, British Journal of Cancer, vol.280, issue.12, pp.1788-95, 2007.
DOI : 10.1038/nm1428

T. Kessler, F. Fehrmann, R. Bieker, W. Berdel, and R. Mesters, Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies, Current Drug Targets, vol.8, issue.2, pp.257-68, 2007.
DOI : 10.2174/138945007779940089

S. Kivivuori, S. Siitonen, K. Porkka, K. Vettenranta, R. Alitalo et al., Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells. Pediatr Blood Cancer, pp.387-92, 2007.

S. Kumar and K. Anderson, Drug Insight: thalidomide as a treatment for multiple myeloma, Nature Clinical Practice Oncology, vol.104, issue.5, pp.262-70, 2005.
DOI : 10.1038/sj.thj.6200401

S. Kumar, T. Witzig, and S. Rajkumar, Thalidomid: current role in the treatment of non-plasma cell malignancies, J Clin Oncol Review. Erratum J Clin Oncol, vol.2222, issue.1214, pp.2477-882973, 2004.

L. Legros and G. Pages, Effet anti-angiogénique de l'imatinib mésylate (Glivec®) dans les leucémies myéloïdes chroniques. Hématologie. 2004 nov-dec, pp.464-471

M. Li, V. Jendrossek, and C. Belka, The role of PDGF in radiation oncology, Radiation Oncology, vol.2, issue.1, p.5, 2007.
DOI : 10.1186/1748-717X-2-5

D. Liao and R. Johnson, Hypoxia: A key regulator of angiogenesis in cancer, Cancer and Metastasis Reviews, vol.112, issue.Suppl 4, pp.281-90, 2007.
DOI : 10.7326/0003-4819-138-8-200304150-00014

S. Liekens, D. Clercq, E. Neyts, and J. , Angiogenesis: regulators and clinical applications, Biochemical Pharmacology, vol.61, issue.3, pp.253-70, 2001.
DOI : 10.1016/S0006-2952(00)00529-3

R. Liersch, C. Schliemann, R. Bieker, H. Hintelmann, T. Buechner et al., Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia, Leukemia Research, vol.32, issue.6, pp.954-61, 2008.
DOI : 10.1016/j.leukres.2007.10.005

C. López-pedrera, N. Barbarroja, G. Dorado, E. Siendones, and F. Velasco, Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies, Leukemia, vol.8, issue.8, 2006.
DOI : 10.1097/00130404-200201000-00003

R. Maffei, R. Marasca, S. Martinelli, I. Castelli, R. Santachiara et al., Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status, Leukemia, vol.7, issue.6, pp.1312-1317, 2007.
DOI : 10.1016/S1525-1578(10)60589-2

M. Marchetti, A. Vignoli, L. Russo, D. Balducci, M. Pagnoncelli et al., Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin, Thrombosis Research, vol.121, issue.5, pp.637-682, 2008.
DOI : 10.1016/j.thromres.2007.06.015

A. Mazar, The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer, Anti-Cancer Drugs, vol.12, issue.5, pp.387-400, 2001.
DOI : 10.1097/00001813-200106000-00001

S. Menon, S. Rajkumar, M. Lacy, P. Falco, and A. Palumbo, Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer, pp.1522-1530, 2008.

F. Meziani, A. Tesse, and R. Andriantsitohaina, Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol Rep, pp.75-84, 2008.

E. Millette, B. Rauch, R. Kenagy, G. Daum, and A. Clowes, Platelet-Derived Growth Factor???BB Transactivates the Fibroblast Growth Factor Receptor to Induce Proliferation in Human Smooth Muscle Cells, Trends in Cardiovascular Medicine, vol.16, issue.1, pp.25-33, 2006.
DOI : 10.1016/j.tcm.2005.11.003

I. Nilsson, C. Rolny, Y. Wu, B. Pytowski, D. Hicklin et al., Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development, The FASEB Journal, vol.18, issue.13, pp.1507-1522, 2004.
DOI : 10.1002/aja.1002030109

K. Norrby, 2.5???kDa and 5.0???kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis, International Journal of Experimental Pathology, vol.53, issue.1, 2000.
DOI : 10.1038/10518

URL : https://hal.archives-ouvertes.fr/hal-00600868

K. Norrby, Low-molecular-weight heparins and angiogenesis., APMIS, vol.155, issue.9, pp.79-102, 2006.
DOI : 10.1074/jbc.M303569200

P. Nyberg, T. Salo, and R. Kalluri, Tumor microenvironment and angiogenesis, Frontiers in Bioscience, vol.Volume, issue.13, pp.6537-53, 2008.
DOI : 10.2741/3173

P. Nyberg, L. Xie, and R. Kalluri, Endogenous inhibitors of angiogenesis.Cancer Res, May, vol.1565, issue.10, pp.3967-79, 2005.

M. Pavic, P. Debourdeau, M. Aletti, D. Farge-bancel, and H. Rousset, Maladie veineuse thromboembolique et??cancer, La Revue de M??decine Interne, vol.27, issue.4, pp.313-335, 2006.
DOI : 10.1016/j.revmed.2005.11.016

M. Pepper, Angiogen??se et morphogen??se de l'arbre vasculaire : de la biologie cellulaire ?? la clinique., m??decine/sciences, vol.16, issue.12, pp.1378-86, 2000.
DOI : 10.4267/10608/1593

G. Petralia, N. Lemoine, and A. Kakkar, Mechanisms of Disease: the impact of antithrombotic therapy in cancer patients, Nature Clinical Practice Oncology, vol.2, issue.7, pp.356-63, 2005.
DOI : 10.1038/ncponc0225

T. Petrova, T. Makinen, and K. Alitalo, Signaling via Vascular Endothelial Growth Factor Receptors, Experimental Cell Research, vol.253, issue.1, pp.117-147, 1999.
DOI : 10.1006/excr.1999.4707

K. Pietras, J. Pahler, G. Bergers, and D. Hanahan, Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting, PLoS Medicine, vol.11, issue.1, p.19, 2008.
DOI : 10.1371/journal.pmed.0050019.st002

K. Podar and K. Anderson, The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications, Blood, vol.105, issue.4, pp.1383-95, 2005.
DOI : 10.1182/blood-2004-07-2909

J. Pouysségur, F. Dayan, and N. Mazure, Hypoxia signalling in cancer and approaches to enforce tumour regression, Nature, vol.9, issue.suppl. 5, pp.437-480, 2006.
DOI : 10.1016/j.devcel.2005.09.010

M. Presta, P. Dell-'era, S. Mitola, E. Moroni, R. Ronca et al., Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis, Cytokine & Growth Factor Reviews, vol.16, issue.2, pp.159-78, 2005.
DOI : 10.1016/j.cytogfr.2005.01.004

D. Rafii, B. Psaila, J. Butler, D. Jin, and D. Lyden, Regulation of Vasculogenesis by Platelet-Mediated Recruitment of Bone Marrow-Derived Cells, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.2, pp.217-239, 2008.
DOI : 10.1161/ATVBAHA.107.151159

S. Rafii, D. Lyden, R. Benezra, K. Hattori, and B. Heissig, Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer, pp.826-861, 2002.

I. Rajantie, M. Ilmonen, A. Alminaite, U. Ozerdem, K. Alitalo et al., Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells, Blood, vol.104, issue.7, pp.2084-2090, 2004.
DOI : 10.1182/blood-2004-01-0336

J. Rak, P. Klement, and Y. J. , Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr Lek, pp.135-143, 2006.

J. Rak, C. Milsom, L. May, P. Klement, and Y. J. , Tissue Factor in Cancer and Angiogenesis: The Molecular Link between Genetic Tumor Progression, Tumor Neovascularization, and Cancer Coagulopathy, Seminars in Thrombosis and Hemostasis, vol.32, issue.01, pp.54-70, 2006.
DOI : 10.1055/s-2006-933341

J. Rak, J. Yu, G. Klement, and R. Kerbel, Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth, Journal of Investigative Dermatology Symposium Proceedings, vol.5, issue.1, pp.24-33, 2000.
DOI : 10.1046/j.1087-0024.2000.00012.x

URL : https://doi.org/10.1046/j.1087-0024.2000.00012.x

B. Ren, K. Yee, J. Lawler, and R. Khosravi-far, Regulation of tumor angiogenesis by thrombospondin-1, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1765, issue.2, pp.178-88, 2006.
DOI : 10.1016/j.bbcan.2005.11.002

D. Ribatti, N. B. Vacca, and A. , Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma, Oncogene, vol.25, issue.31, pp.4257-66, 2006.
DOI : 10.1038/sj.onc.1209456

P. Richardson, R. Schlossman, S. Jagannath, M. Alsina, R. Desikan et al., Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity, Mayo Clinic Proceedings, vol.79, issue.7, pp.875-82, 2004.
DOI : 10.4065/79.7.875

F. Rickles, S. Patierno, and P. Fernandez, Tissue Factor, Thrombin, and Cancer, Chest, vol.124, issue.3, pp.58-68, 2003.
DOI : 10.1378/chest.124.3_suppl.58S

H. Robins, O. Neill, A. Gilbert, M. Olsen, M. Sapiente et al., Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial, Cancer Chemotherapy and Pharmacology, vol.25, issue.suppl 1, pp.227-260, 2008.
DOI : 10.1007/s00280-007-0596-3

C. Roca and R. Adams, Regulation of vascular morphogenesis by Notch signaling. Genes Dev, Oct, vol.1521, issue.20, pp.2511-2535, 2007.

C. Rüegg, Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions, Journal of Leukocyte Biology, vol.35, issue.4, pp.682-686, 2006.
DOI : 10.1080/07853890310017053

W. Ruf, Redundant signaling of tissue factor and thrombin in cancer progression?, Journal of Thrombosis and Haemostasis, vol.63, issue.8, pp.1584-1591, 2007.
DOI : 10.1038/nm1037

J. Rundhaug, Matrix metalloproteinases and angiogenesis, Journal of Cellular and Molecular Medicine, vol.9, issue.2, pp.267-85, 2005.
DOI : 10.1073/pnas.220399597

P. Saharinen, L. Eklund, J. Miettinen, R. Wirkkala, A. Anisimov et al., Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell???cell and cell???matrix contacts, Nature Cell Biology, vol.19, issue.5, pp.527-564, 2008.
DOI : 10.1074/jbc.M500292200

M. Sato, W. Arap, and R. Pasqualini, Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology (Williston Park), pp.1346-52, 1367.

C. Schliemann, R. Bieker, T. Padro, T. Kessler, H. Hintelmann et al., Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia, Haematologica, vol.91, issue.9, pp.1203-1214, 2006.

C. Schliemann, R. Bieker, N. Thoennissen, J. Gerss, R. Liersch et al., Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia, Leukemia, vol.93, issue.9, pp.1901-1907, 2007.
DOI : 10.1016/j.ccr.2004.09.030

M. Shibuya, Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis, Angiogenesis, vol.79, issue.4, pp.225-255, 2006.
DOI : 10.4049/jimmunol.174.1.215

M. Shibuya, Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis, BMB Reports, vol.41, issue.4, pp.278-86, 2008.
DOI : 10.5483/BMBRep.2008.41.4.278

W. Shim, I. Ho, and P. Wong, Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis, Molecular Cancer Research, vol.5, issue.7, pp.655-65, 2007.
DOI : 10.1158/1541-7786.MCR-07-0072

J. Silvestre and B. Lévy, Role of matrix proteolysis in angiogenesis, Journ Annu Diabetol Hotel Dieu, pp.23-32, 2002.

S. Tabruyn and A. Griffioen, Molecular pathways of angiogenesis inhibition, Biochemical and Biophysical Research Communications, vol.355, issue.1, pp.1-5, 2007.
DOI : 10.1016/j.bbrc.2007.01.123

T. Tammela, G. Zarkada, E. Wallgard, A. Murtomäki, S. Suchting et al., Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation, Nature, vol.196, issue.7204, pp.656-60, 2008.
DOI : 10.1161/01.RES.88.6.623

H. Takahashi and M. Shibuya, The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions, Clinical Science, vol.109, issue.3, pp.227-268, 2005.
DOI : 10.1042/CS20040370

P. Ten-dijke and H. Arthur, Extracellular control of TGF?? signalling in vascular development and disease, Nature Reviews Molecular Cell Biology, vol.355, issue.11, pp.857-69, 2007.
DOI : 10.1161/01.HYP.28.5.881

S. Teo, Properties of thalidomide and its analogues: Implications for anticancer therapy, The AAPS Journal, vol.7, issue.1, pp.14-19, 2005.
DOI : 10.1208/aapsj070103

M. Uutela, M. Wirzenius, K. Paavonen, I. Rajantie, Y. He et al., PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis, Blood, vol.104, issue.10, pp.3198-204, 2004.
DOI : 10.1182/blood-2004-04-1485

URL : http://www.bloodjournal.org/content/bloodjournal/104/10/3198.full.pdf

A. Vacca and D. Ribatti, Bone marrow angiogenesis in multiple myeloma, Leukemia, vol.19, issue.2, pp.193-202, 2006.
DOI : 10.1038/sj.leu.2403776

A. Vacca, C. Scavelli, V. Montefusco, D. Pietro, G. Neri et al., Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.23, pp.5334-5380, 2005.
DOI : 10.1200/JCO.2005.03.723

W. Van-heeckeren, S. Sanborn, A. Narayan, M. Cooney, K. Mccrae et al., Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis, Current Opinion in Hematology, vol.14, issue.5, pp.468-80, 2007.
DOI : 10.1097/MOH.0b013e3282a6457f

B. Vandenbunder, Mécanismes moléculaires de l'angiogénèse. Hématologie. 1997 may-jun, pp.221-230

H. Versteeg, F. Schaffner, M. Kerver, H. Petersen, J. Ahamed et al., Inhibition of tissue factor signaling suppresses tumor growth, Blood, vol.111, issue.1, pp.190-199, 2008.
DOI : 10.1182/blood-2007-07-101048

A. Vignoli, M. Marchetti, D. Balducci, T. Barbui, and A. Falanga, Differential effect of the low-molecularweight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties Erratum in: Haematologica, Haematologica. Feb, vol.91, issue.2, pp.207-221, 2006.

I. Vlodavsky, N. Ilan, Y. Nadir, B. Brenner, B. Katz et al., Heparanase, heparin and the coagulation system in cancer progression, Thrombosis Research, vol.120, issue.2, pp.112-132, 2007.
DOI : 10.1016/S0049-3848(07)70139-1

S. Wickström and K. Alitalo, Endostatin Signaling and Regulation of Endothelial Cell???Matrix Interactions, Adv Cancer Res, vol.94, pp.197-229, 2005.
DOI : 10.1016/S0065-230X(05)94005-0

J. Yu, L. May, V. Lhotak, S. Shahrzad, S. Shirasawa et al., Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis, Blood, vol.105, issue.4, pp.1734-1775, 2005.
DOI : 10.1182/blood-2004-05-2042

X. Zhang and J. Lawler, Thrombospondin-based antiangiogenic therapy, Microvascular Research, vol.74, issue.2-3, pp.90-99, 2007.
DOI : 10.1016/j.mvr.2007.04.007

URL : http://europepmc.org/articles/pmc4696437?pdf=render